The rat models for peripheral nerve regeneration looked really good (comparison of GelGro nerve regen. versus suture). They need to do the same with humans otherwise there's no basis for comparing Celgro versus standard treatment. If there's no basis for comparison, then there's no telling if it's an advancement on suturing. Geting a neurosurgeon on board would be a good thing. They are the ones who are usually tasked with doing these sorts of procedures. Taking meaurements for opiate use is immaterial because ruptured peripheral nerves are not usually painful. Lots of problems with methodology and data presentation need ironing out. Outsourcing the research side of things to a university might be an option.
Don't blame me for the share price drop. It would have happened anyway. I wouldn't be the only one thinking like this. There's huge potential, but it needs to be properly demonstrated.
- Forums
- ASX - By Stock
- OCC
- Ann: CelGro Nerve Regeneration Results in Quadriplegic Patients
Ann: CelGro Nerve Regeneration Results in Quadriplegic Patients, page-200
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
63.0¢ |
Change
0.005(0.80%) |
Mkt cap ! $148.2M |
Open | High | Low | Value | Volume |
63.5¢ | 64.0¢ | 61.5¢ | $130.1K | 207.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 29715 | 62.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
63.0¢ | 23412 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 29640 | 0.625 |
6 | 59433 | 0.620 |
7 | 123373 | 0.615 |
7 | 121215 | 0.610 |
12 | 243891 | 0.605 |
Price($) | Vol. | No. |
---|---|---|
0.630 | 12776 | 4 |
0.640 | 16795 | 3 |
0.645 | 20124 | 3 |
0.650 | 18551 | 3 |
0.660 | 11295 | 3 |
Last trade - 11.25am 18/11/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online